HZNP Horizon Therapeutics Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: HZNP

Price (delayed)

$82.03

Market cap

$18.86B

P/E Ratio

21.64

Dividend/share

N/A

EPS

$3.79

Enterprise value

$19.78B

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise ...

Highlights
Horizon Therapeutics's EPS has soared by 187% YoY and by 60% from the previous quarter
Horizon Therapeutics's quick ratio has surged by 74% YoY and by 13% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.horizontherapeutics.com
Peers: AMGN RDUS MRK PFE

Key stats

What are the main financial stats of HZNP
Market
Shares outstanding
229.88M
Market cap
$18.86B
Enterprise value
$19.78B
Valuations
Price to earnings (P/E)
21.64
Price to book (P/B)
3.9
Price to sales (P/S)
4.99
EV/EBIT
22.09
EV/EBITDA
15.53
EV/Sales
5.25
Earnings
Revenue
$3.77B
EBIT
$895.53M
EBITDA
$1.27B
Free cash flow
$1.18B
Per share
EPS
$3.79
Free cash flow per share
$5.17
Book value per share
$21.02
Revenue per share
$16.45
TBVPS
$20.96
Balance sheet
Total assets
$8.74B
Total liabilities
$3.92B
Debt
$2.57B
Equity
$4.82B
Working capital
$2.12B
Liquidity
Debt to equity
0.53
Current ratio
3.57
Quick ratio
2.83
Net debt/EBITDA
0.72
Margins
EBITDA margin
33.8%
Gross margin
75.9%
Net margin
22.9%
Operating margin
23.8%
Efficiency
Return on assets
10.1%
Return on equity
19.1%
Return on invested capital
18.2%
Return on capital employed
11.3%
Return on sales
23.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HZNP stock price

How has the Horizon Therapeutics stock price performed over time
Intraday
0.42%
1 week
-1.1%
1 month
-13.51%
1 year
-13.53%
YTD
-23.88%
QTD
-22.03%

Financial performance

How have Horizon Therapeutics's revenue and profit performed over time
Revenue
$3.77B
Gross profit
$2.86B
Operating income
$895.29M
Net income
$862.1M
Gross margin
75.9%
Net margin
22.9%
The operating income has surged by 154% year-on-year and by 64% since the previous quarter
The company's net margin has surged by 79% YoY and by 38% QoQ
HZNP's gross profit has soared by 73% year-on-year and by 18% since the previous quarter
Horizon Therapeutics's revenue has soared by 72% YoY and by 17% from the previous quarter

Growth

What is Horizon Therapeutics's growth rate over time

Valuation

What is Horizon Therapeutics stock price valuation
P/E
21.64
P/B
3.9
P/S
4.99
EV/EBIT
22.09
EV/EBITDA
15.53
EV/Sales
5.25
Horizon Therapeutics's EPS has soared by 187% YoY and by 60% from the previous quarter
The stock's price to earnings (P/E) is 45% less than its last 4 quarters average of 38.9
HZNP's price to book (P/B) is 25% lower than its last 4 quarters average of 5.2 but 8% higher than its 5-year quarterly average of 3.6
The equity is up by 25% year-on-year and by 3.1% since the previous quarter
Horizon Therapeutics's revenue has soared by 72% YoY and by 17% from the previous quarter
HZNP's price to sales (P/S) is 35% less than its last 4 quarters average of 7.6

Efficiency

How efficient is Horizon Therapeutics business performance
HZNP's ROE has soared by 139% YoY and by 53% from the previous quarter
Horizon Therapeutics's return on assets has surged by 120% YoY and by 58% QoQ
Horizon Therapeutics's ROS has soared by 63% YoY and by 41% from the previous quarter
HZNP's return on invested capital has surged by 63% since the previous quarter and by 46% year-on-year

Dividends

What is HZNP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HZNP.

Financial health

How did Horizon Therapeutics financials performed over time
The total assets is 123% more than the total liabilities
Horizon Therapeutics's quick ratio has surged by 74% YoY and by 13% QoQ
Horizon Therapeutics's current ratio has surged by 51% YoY and by 13% QoQ
The company's debt is 47% lower than its equity
The equity is up by 25% year-on-year and by 3.1% since the previous quarter
The debt to equity has declined by 21% year-on-year and by 3.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.